Tarsus grants Neera Clase 10,587 stock options

The chief commercial officer’s options and RSUs have separate vesting schedules, both subject to continuous service.

Available on EDGAR 11/05/2026 - 04:40 PM EST Accepted by SEC EDGAR 11/05/2026 - 04:40 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. Chief Commercial Officer Neera Clase received 10,587 stock options to buy common shares and 6,678 restricted stock units on November 3, 2026. The options have a $72.64 per-share exercise price and expire November 2, 2036. Twenty-five percent of the option shares vest on November 1, 2027, with 1/48th vesting monthly thereafter for three years. The RSUs vest in four equal annual installments on December 15 of 2027, 2028, 2029 and 2030. Both awards are subject to continuous service. Her reported direct positions following the awards were 10,587 options and 6,678 RSUs.

Insider Trade Summary

Grant/Award: 17,265 shares

Grant/Award 2 txns

Insider Clase Neera

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	10,587	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	6,678	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,587 contracts (Direct); Restricted Stock Units — 6,678 contracts (Direct)

Footnotes (3)

1. F1. 25% of the option shares shall vest on November 1, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
2. F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. F3. The RSUs will vest in four equal annual installments on December 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

Key Figures

Stock options awarded: 10,587 options Restricted stock units awarded: 6,678 RSUs Option exercise price: $72.64 per share +2 more

5 metrics

Stock options awarded 10,587 options Awarded November 3, 2026; each option is a right to buy a common share.

Restricted stock units awarded 6,678 RSUs Awarded November 3, 2026.

Option exercise price $72.64 per share Exercise price for the awarded options.

Option expiration November 2, 2036 Expiration date for the awarded options.

RSU vesting schedule Four equal annual installments December 15 of 2027, 2028, 2029 and 2030, subject to continuous service.

Key Terms

Restricted Stock Unit, exercise price, continuous service

3 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents a contingent right"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

exercise price financial

"conversion_or_exercise_price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"subject to the Reporting Person's continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options and RSUs did TARS’s chief commercial officer receive?

Neera Clase, Tarsus Pharmaceuticals’ Chief Commercial Officer, received 10,587 stock options and 6,678 RSUs on November 3, 2026. The options have a $72.64 per-share exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clase Neera

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

17700 LAGUNA CANYON ROAD, FLOOR 4

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$72.64	11/03/2026		A		10,587		(1)	11/02/2036	Common Stock	10,587	$0	10,587	D
Restricted Stock Units	(2)	11/03/2026		A		6,678		(3)	(3)	Common Stock	6,678	$0	6,678	D

Explanation of Responses:

1. 25% of the option shares shall vest on November 1, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. The RSUs will vest in four equal annual installments on December 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Scott Sieckert, Attorney-in-Fact	11/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)